175 related articles for article (PubMed ID: 11918843)
1. Molecular simulation of interaction between estrogen receptor and selective estrogen receptor modulators.
Guo ZR; Yi X; Xu ZB
Acta Pharmacol Sin; 2002 Mar; 23(3):208-12. PubMed ID: 11918843
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptor modulators: identification and structure-activity relationships of potent ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Halleux C; Kallen J; Keller H; Schlaeppi JM; Stark W
J Med Chem; 2003 Jul; 46(14):2945-57. PubMed ID: 12825935
[TBL] [Abstract][Full Text] [Related]
3. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
[TBL] [Abstract][Full Text] [Related]
5. Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brain.
Sumner BE; Grant KE; Rosie R; Hegele-Hartung Ch; Fritzemeier KH; Fink G
Neurosci Lett; 2007 Apr; 417(1):95-9. PubMed ID: 17398000
[TBL] [Abstract][Full Text] [Related]
6. A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.
Baytur YB; Ozbilgin K; Cilaker S; Lacin S; Kurtul O; Oruc S; Koyuncu FM
Eur J Obstet Gynecol Reprod Biol; 2007 Nov; 135(1):94-103. PubMed ID: 16973256
[TBL] [Abstract][Full Text] [Related]
7. Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction.
Carlson KE; Choi I; Gee A; Katzenellenbogen BS; Katzenellenbogen JA
Biochemistry; 1997 Dec; 36(48):14897-905. PubMed ID: 9398213
[TBL] [Abstract][Full Text] [Related]
8. Structural aspects of agonism and antagonism in the oestrogen receptor.
Pike AC; Brzozowski AM; Walton J; Hubbard RE; Bonn T; Gustafsson JA; Carlquist M
Biochem Soc Trans; 2000; 28(4):396-400. PubMed ID: 10961927
[TBL] [Abstract][Full Text] [Related]
9. Prediction of ligand binding affinity and orientation of xenoestrogens to the estrogen receptor by molecular dynamics simulations and the linear interaction energy method.
van Lipzig MM; ter Laak AM; Jongejan A; Vermeulen NP; Wamelink M; Geerke D; Meerman JH
J Med Chem; 2004 Feb; 47(4):1018-30. PubMed ID: 14761204
[TBL] [Abstract][Full Text] [Related]
10. Estradiol and raloxifene decrease the formation of multinucleate cells in human bone marrow cultures.
Ramalho AC; Couttet P; Baudoin C; Morieux C; Graulet AM; de Vernejoul MC; Cohen-Solal ME
Eur Cytokine Netw; 2002; 13(1):39-45. PubMed ID: 11956019
[TBL] [Abstract][Full Text] [Related]
11. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer.
Jordan VC; O'Malley BW
J Clin Oncol; 2007 Dec; 25(36):5815-24. PubMed ID: 17893378
[TBL] [Abstract][Full Text] [Related]
12. Effects of two novel selective estrogen receptor modulators, raloxifene, tamoxifen, and ethinyl estradiol on the uterus, vagina and breast in ovariectomized cynomolgus monkeys (Macaca fascicularis).
Sikoski P; Register TC; Lees CJ; Lundeen S; Hutchison J; Brown KH; Cline JM
Am J Obstet Gynecol; 2007 Jan; 196(1):75.e1-7. PubMed ID: 17240242
[TBL] [Abstract][Full Text] [Related]
13. Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance.
Lewis JS; Jordan VC
Mutat Res; 2005 Dec; 591(1-2):247-63. PubMed ID: 16083919
[TBL] [Abstract][Full Text] [Related]
14. QSAR of estrogen receptor modulators: exploring selectivity requirements for ER(alpha) versus ER(beta) binding of tetrahydroisoquinoline derivatives using E-state and physicochemical parameters.
Mukherjee S; Saha A; Roy K
Bioorg Med Chem Lett; 2005 Feb; 15(4):957-61. PubMed ID: 15686893
[TBL] [Abstract][Full Text] [Related]
15. Novel structural templates for estrogen-receptor ligands and prospects for combinatorial synthesis of estrogens.
Fink BE; Mortensen DS; Stauffer SR; Aron ZD; Katzenellenbogen JA
Chem Biol; 1999 Apr; 6(4):205-19. PubMed ID: 10099132
[TBL] [Abstract][Full Text] [Related]
16. [Molecular mechanism of tissue-specific actions of SERM].
Kato S
Clin Calcium; 2006 Sep; 16(9):1469-74. PubMed ID: 16951470
[TBL] [Abstract][Full Text] [Related]
17. Novel estrogen receptor ligands based on an anthranylaldoxime structure: role of the phenol-type pseudocycle in the binding process.
Minutolo F; Antonello M; Bertini S; Ortore G; Placanica G; Rapposelli S; Sheng S; Carlson KE; Katzenellenbogen BS; Katzenellenbogen JA; Macchia M
J Med Chem; 2003 Sep; 46(19):4032-42. PubMed ID: 12954056
[TBL] [Abstract][Full Text] [Related]
18. A molecular docking study of estrogenically active compounds with 1,2-diarylethane and 1,2-diarylethene pharmacophores.
Kekenes-Huskey PM; Muegge I; von Rauch M; Gust R; Knapp EW
Bioorg Med Chem; 2004 Dec; 12(24):6527-37. PubMed ID: 15556769
[TBL] [Abstract][Full Text] [Related]
19. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.
Jordan VC
J Med Chem; 2003 Mar; 46(7):1081-111. PubMed ID: 12646017
[No Abstract] [Full Text] [Related]
20. Analysis of 3D models of octopus estrogen receptor with estradiol: evidence for steric clashes that prevent estrogen binding.
Baker ME; Chandsawangbhuwana C
Biochem Biophys Res Commun; 2007 Sep; 361(3):782-8. PubMed ID: 17678875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
